ArticleJournal of autism and developmental disorders2026
Fatty Acid Supplementation in Toddlers Born Preterm and Attention and Autism Outcomes at 8-10 Years: Omega Tots Randomized Controlled Trial Long-Term Follow-Up.
Article in Journal of autism and developmental disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05191823 (Long-term Effects and Safety of DHA+AA Supplementation in Toddlerhood for Children Born Preterm), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Long-term Effects and Safety of DHA+AA Supplementation in Toddlerhood for Children Born Preterm
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeChildren born preterm are at increased likelihood of autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD). We examined whether 6 months of daily dietary docosahexaenoic acid (DHA) + arachidonic acid (AA) supplementation at age 1-year reduced attention problems and likelihood of ADHD and ASD diagnoses in children born preterm.
methodsIn the Omega Tots randomized placebo-controlled trial, children born at <35 weeks' gestation received daily DHA (200 mg) + AA (200 mg) or placebo (400 mg corn oil) at 10-16 months' corrected age. This long-term follow-up assessed outcomes at 8.5-10.5 years. Outcomes included parent- and teacher-rated attention problems, performance on the Flanker Inhibitory Control and Attention Test (continuous performance task), and medical record diagnoses of ASD and ADHD. Mixed linear and log-binomial regression models estimated treatment effects. Subgroup analyses examined effects by sex, birthweight, family income, dietary omega-3 intake, and blood omega-3 status.
resultsAt least 1 outcome measure was available for all 376 children eligible for follow-up. Flanker scores were higher (better) for the DHA+AA group (difference=3.02; 95% CI=0.01, 6.04), particularly among children with lower dietary omega-3 intake (difference=4.88; 95% CI=0.53, 9.23). DHA+AA was associated with fewer teacher-rated attention problems among children with birthweight>1500g (difference=-2.97; 95% CI=-5.38, -0.55). No group differences were found in likelihood of autism and ADHD diagnoses.
conclusionsDHA+AA supplementation was associated with modest improvements in attention, particularly among specific subgroups, supporting further investigation of targeted, personalized nutrition approaches. There was no association between supplementation and likelihood of ADHD and autism. CLINICAL
trial registrationClinicalTrials.gov Identifier: NCT05191823.
Indexed as
Identifiers
42911477What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.